{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:58:52Z","timestamp":1790276332468,"version":"4.1.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"\n Background:<\/jats:title>\n The pharmacokinetic (PK) data of ganciclovir (GCV), a first-line antiviral treatment for cytomegalovirus infections, in critically ill patients are limited. This study aimed at characterizing GCV population PK and interindividual variability (IIV) in intensive care unit (ICU) patients. Secondary objectives were to identify patient characteristics responsible for IIV and simulate GCV exposure for different dosing regimens.<\/jats:p>\n <\/jats:sec>\n \n Method:<\/jats:title>\n In this retrospective observational study, clinical data and serum GCV levels were collected from ICU patients on intravenous GCV. PK modeling, covariate analyses, and explorative Monte Carlo dosing simulations (MCS) were performed using nonlinear mixed-effects modeling. Bootstrap and visual predictive checks were used to determine model adequacy.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n In total, 128 GCV measurements were obtained from 34 patients. GCV PK conformed to a 1-compartment model with first-order elimination. After multivariate analyses, only the estimated glomerular filtration rate calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula (P<\/jats:italic> < 0.001) was included as a covariate. In the final model, the estimated clearance (CL) and volume of distribution (V1) were 2.3 L\/h and 42 L, respectively, for a patient with the median CKD-EPI of the population (65 mL\/min per 1.73 m2<\/jats:sup>). The association between CKD-EPI and CL decreased the residual variability from 0.56 to 0.43 and V1-IIV from 114% to 80%, whereas CL-IIV changed from 43% to 47%. MCS revealed that a substantial number of patients may not achieve the GCV PK\/pharmacodynamic target trough level (>1.5 mg\/L) when administering the label-recommended dose reductions for patients with CKD-EPI <50 mL\/min.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n A large IIV was observed in GCV PK among ICU patients. CKD-EPI could partially explain the IIV, although a large part of the variability remains unclear. MCS suggested that recommended dose reductions for CKD-EPI <50 mL\/min may lead to subtherapeutic plasma GCV levels in these patients.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000689","type":"journal-article","created":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T07:46:49Z","timestamp":1566028009000},"page":"295-301","source":"Crossref","is-referenced-by-count":12,"title":["Population Pharmacokinetics of Ganciclovir in Critically Ill Patients"],"prefix":"10.1097","volume":"42","author":[{"given":"Stefanie D.","family":"Krens","sequence":"first","affiliation":[{"name":"Department of Hospital Pharmacy, Amsterdam University Medical Centers, Amsterdam;"},{"name":"Department of Pharmacy, Radboud University Medical Center, Nijmegen;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caspar J.","family":"Hodiamont","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Amsterdam University Medical Centers, Amsterdam; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole P.","family":"Juffermans","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron A.A.","family":"Math\u00f4t","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Amsterdam University Medical Centers, Amsterdam;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinier M.","family":"van Hest","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Amsterdam University Medical Centers, Amsterdam;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0002-9394(01)01322-8","article-title":"Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy","volume":"133","author":"Jabs","year":"2002","journal-title":"Am J Ophthalmol."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"e2016031","DOI":"10.4084\/mjhid.2016.031","article-title":"CMV in hematopoietic stem cell transplantation","volume":"8","author":"de la C\u00e1mara","year":"2016","journal-title":"Mediterr J Hematol Infect Dis."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"R68","DOI":"10.1186\/cc7875","article-title":"Cytomegalovirus infection in critically ill patients: a systematic review","volume":"13","author":"Osawa","year":"2009","journal-title":"Crit Care."},{"issue":"suppl 3","key":"R5-20230814","doi-asserted-by":"crossref","first-page":"S507","DOI":"10.1093\/clinids\/10.Supplement_3.S507","article-title":"Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function","volume":"10","author":"Sommadossi","year":"1988","journal-title":"Rev Infect Dis."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1517\/17425255.2013.799137","article-title":"Drug absorption, distribution, metabolism and excretion considerations in critically ill adults","volume":"9","author":"Roberts","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11318140-000000000-00000","article-title":"Augmented renal clearance: implications for antibacterial dosing in the critically ill","volume":"49","author":"Udy","year":"2010","journal-title":"Clin Pharmacokinet."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1128\/AAC.00892-13","article-title":"Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically Ill patients","volume":"58","author":"Horvatits","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF02425056","article-title":"Clinical use of ganciclovir during renal failure and continuous hemodialysis","volume":"20","author":"Bastien","year":"1994","journal-title":"Intensive Care Med."},{"key":"R11-20230814","first-page":"650","article-title":"Clinical pharmacy: case studies: case number 25 gentamicin therapy","volume":"8","author":"McCarron","year":"1974","journal-title":"Drug Intell Clin Pharm."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1056\/NEJM199609053351007","article-title":"Ganciclovir","volume":"335","author":"Crumpacker","year":"1996","journal-title":"N Engl J Med."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/infdis\/152.4.833","article-title":"Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine","volume":"152","author":"Plotkin","year":"1985","journal-title":"J Infect Dis."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/infdis\/168.2.332","article-title":"Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis","volume":"168","author":"Boivin","year":"1993","journal-title":"J Infect Dis."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/01.TP.0000164512.99703.AD","article-title":"Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients","volume":"79","author":"Wiltshire","year":"2005","journal-title":"Transplantation."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1128\/AAC.39.10.2350","article-title":"Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling","volume":"39","author":"Yuen","year":"1995","journal-title":"Antimicrob Agents Chemother."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1097\/TP.0b013e3182000042","article-title":"Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days","volume":"90","author":"Welker","year":"2010","journal-title":"Transplantation."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1128\/AAC.00085-09","article-title":"Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus","volume":"53","author":"Cald\u00e9s","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1067\/mcp.2002.126306","article-title":"Pharmacokinetics of valganciclovir and ganciclovir in renal impairment","volume":"72","author":"Czock","year":"2002","journal-title":"Clin Pharmacol Ther."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1186\/s13054-014-0657-z","article-title":"Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds","volume":"18","author":"Udy","year":"2014","journal-title":"Crit Care."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1124\/dmd.111.042036","article-title":"Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs","volume":"40","author":"Cheng","year":"2012","journal-title":"Drug Metab Dispos."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/00003088-200948060-00006","article-title":"Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements","volume":"53","author":"Perrottet","year":"2009","journal-title":"Clin Pharmacokinet."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00134-015-3934-7","article-title":"Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study","volume":"41","author":"Hoste","year":"2015","journal-title":"Intensive Care Med."},{"key":"R30-20230814","first-page":"408","article-title":"Ganciclovir therapeutic drug monitoring: a case series","volume":"40","author":"Martson","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s40262-018-0638-5","article-title":"Valganciclovir pharmacokinetics in patients receiving oral prophylaxis following kidney transplantation and model-based predictions of optimal dosing regimens","volume":"57","author":"T\u00e4ngd\u00e9n","year":"2018","journal-title":"Clin Pharmacokinet."},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"R73","DOI":"10.1186\/cc4915","article-title":"RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis","volume":"10","author":"Hoste","year":"2006","journal-title":"Crit Care."},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/ki.2011.339","article-title":"AKI in the ICU: definition, epidemiology, risk stratification, and outcomes","volume":"81","author":"Singbartl","year":"2012","journal-title":"Kidney Int."},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijantimicag.2016.10.022","article-title":"Determinants of gentamicin concentrations in critically ill patients: a population pharmacokinetic analysis","volume":"49","author":"Hodiamont","year":"2017","journal-title":"Int J Antimicrob Agents."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000689","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:37:45Z","timestamp":1692052665000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000689","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}